It has been another busy week for Australia’s top brokers. This has led to the release of a large number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone:
Australian Clinical Labs Ltd (ASX: ACL)
According to a note out of Goldman Sachs, its analysts have retained their buy rating and increased their price target on this pathology company’s shares to $6.60. Goldman notes that Australian Clinical Labs has upgraded its first half guidance for the fourth time thanks to strong demand for COVID-19 testing and a solid performance from its base business. The broker believes testing volumes could remain high for some time yet and expects the company to benefit greatly. The Australian Clinical Labs share price is trading at $5.81 on Thursday.
Lovisa Holdings Ltd (ASX: LOV)
A note out of UBS reveals that its analysts have initiated coverage on this fashion jewellery retailer’s shares with a buy rating and $21.25 price target. The broker likes Lovisa due to its strong position in a fragmented market. Furthermore, UBS expects the company to benefit from reopening tailwinds, operating leverage, and its store expansion. In respect to the latter, UBS sees significant room for Lovisa to expand its store network globally in the future. The Lovisa share price is fetching $19.47 this afternoon.
Rio Tinto Limited (ASX: RIO)
Analysts at Citi have retained their buy rating and $115.00 price target on this mining giant’s shares. This follows news that Rio Tinto has acquired the Rincon Lithium project in Argentina for US$825 million. Citi notes that the project has the potential to be a low cost, low carbon footprint brine project of 50ktpa LCE. The broker appears to be a fan of the move and feels it confirms Rio Tinto’s ambition to be a serious player in lithium/battery materials. The Rio Tinto share price is trading at $99.32 today.
The post Brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of August 16th 2021
More reading
- ASX 200 (ASX:XJO) midday update: Medibank and NIB rise, Bega sinks
- Is Rio Tinto (ASX:RIO) paying too much for the Rincon lithium project?
- Why Brickworks, Charter Hall, Magellan, and Rio Tinto shares are falling
- Why Afterpay, Lovisa, Liontown, and Pilbara Minerals shares are racing higher
- ASX 200 (ASX:XJO) midday update: Rio Tinto’s lithium acquisition, Pilbara Minerals jumps
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited and Lovisa Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3H9OQS7
Leave a Reply